Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection

Capital Medical University logo

Capital Medical University

Status

Unknown

Conditions

Acute Aortic Dissection

Treatments

Drug: Edaravone
Drug: Tranexamic acid
Drug: Ulinastatin

Study type

Interventional

Funder types

Other

Identifiers

NCT01894334
2011-2006-03

Details and patient eligibility

About

The morbidity rate of Stanford A type Acute Aortic Dissection(AAD) has been increasing, about 5-10/100,000* per year. Emergency surgery has been the main treatment for Acute Aortic Dissection, however perioperative mortality rate can be as high as 15~30%. Acute lung injury (ALI) is one of the main complications that happen during the perioperative period, which by itself covers 30%-50% of the overall mortality rate. Both domestic and foreign countries lack researches on risk factors, pathogenesis, disease progression and outcome of ALI, which happen during the perioperative period of Acute Aortic Dissection patients. This topic study follow projects in the preoperative of Acute Aortic Dissection'surgery hemodynamic changes (aortic dissection resulting in acute aortic regurgitation, cardiac tamponade and proximal high blood pressure) ischemia - reperfusion injury of aortic dissection distal organ Aortic intima-media exposure cause coagulation / fibrinolytic system function disorder systemic inflammatory response syndrome; use relevant clinical radiographic parameters, indicators of respiratory mechanics (oxygenation index and lung injury index) and biochemical indicators. To discuss risk factors and possible mechanisms of ADD patients with pre-operative ALI and observe their influences on the progress and prognosis of AAD, to explore early intervention in the preoperative for possible risk factors and mechanisms and to evaluate their influences on the prognosis, to achieve the purpose of reducing AAD perioperative mortality of ALI and medical expenses.

Enrollment

220 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

AAD patients within 48 hrs of onset who are prepared for aortic surgery Age between 18 and 70 Willing to sign the informed consent

Exclusion criteria

A history of chronic respiratory disease before onset A history of chronic heart failure or coronary heart disease before onset A history of chronic liver or kidney dysfunction before onset Severe central nervous system syndrome after admission Refuse to sign the informed consent

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

220 participants in 4 patient groups

Control group
No Intervention group
Description:
no intervention
Tranexamic acid group
Experimental group
Description:
tranexamic acid ,intravenous 30mg/kg/d,Preoperative
Treatment:
Drug: Tranexamic acid
Edaravone group
Experimental group
Description:
edaravone, iv, 1mg/kg/d,Preoperative
Treatment:
Drug: Edaravone
Ulinastatin group
Experimental group
Description:
Ulinastatin ,iv,20,000 U /kg/d,Preoperative
Treatment:
Drug: Ulinastatin

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems